EXPERIMENTAL THERAPY OF HOMOZYGOUS PROTEIN C DEFICIENCY

纯合蛋白 C 缺乏症的实验治疗

• 批准号: 3863396
• 负责人: MARILYN J MANCO-JOHNSON
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3863396
• 关键词: anticoagulants; drug administration routes; human therapy evaluation; nutrition related tag; protein C; protein deficiency; relapse /recurrence; thrombocytopenic purpura

Homozygous protein c deficiency is currently a fatal disorder with death from recurrent purpura fulmains and massive venous thrombosis occurring in the first few years of life. This protocol will employ aggressive oral anticoagulation in an attempt to control progressive thrombosis.

纯合子蛋白c缺乏症目前是一种致命的疾病与死亡 复发性紫癜和大面积静脉血栓形成， 生命的最初几年。该方案将采用积极的口头 抗凝治疗以控制进展性血栓形成。